IMPACT EU project
The IMPACT ACM Project is a research initiative focused on advancing the diagnosis and treatment of Arrhythmogenic Cardiomyopathy (ACM), a genetic disease causing ventricular arrhythmias and sudden cardiac death, particularly in young individuals. The project aims to integrate large-scale '-omics' data from ACM patients with clinical information and data from preclinical models. It leverages Artificial Intelligence (AI), specifically unsupervised mixed-data clustering and phenomapping, to identify phenotypic subgroups, discover therapeutically actionable targets, and stratify patients. Key partners include Università degli Studi di Padova, Consorzio Italbiotec, Maastricht University, KSILINK, Italfarmaco Spa, UMC Utrecht, and Lutech Advanced Solutions SPA. The project develops preclinical models, such as 3D in vitro cardiac microtissues, to understand disease mechanisms and identify potential drug targets.
IMPACT EU project
The IMPACT ACM Project is a research initiative focused on advancing the diagnosis and treatment of Arrhythmogenic Cardiomyopathy (ACM), a genetic disease causing ventricular arrhythmias and sudden cardiac death, particularly in young individuals. The project aims to integrate large-scale '-omics' data from ACM patients with clinical information and data from preclinical models. It leverages Artificial Intelligence (AI), specifically unsupervised mixed-data clustering and phenomapping, to identify phenotypic subgroups, discover therapeutically actionable targets, and stratify patients. Key partners include Università degli Studi di Padova, Consorzio Italbiotec, Maastricht University, KSILINK, Italfarmaco Spa, UMC Utrecht, and Lutech Advanced Solutions SPA. The project develops preclinical models, such as 3D in vitro cardiac microtissues, to understand disease mechanisms and identify potential drug targets.